Poor Concentration: Drugs That Cause or Treat It

Why Medications Are an Overlooked Cause of Poor Concentration

A new focus complaint in a patient already taking three or more prescriptions is more likely pharmacological than psychiatric. Polypharmacy-related cognitive impairment affects an estimated 15-25% of older adults on five or more medications, according to a 2019 analysis in the Journal of the American Geriatrics Society (1). The mechanism is not always sedation. Some drugs compete for acetylcholine receptors, others alter dopamine turnover, and a third group simply disrupts sleep architecture enough to erode next-day attention.

The American Geriatrics Society Beers Criteria, updated in 2023, explicitly flags anticholinergic and sedative-hypnotic drugs as high-risk for cognitive adverse effects (2). "Clinicians should review every medication on the list before attributing concentration loss to aging or a new psychiatric diagnosis," the guideline states. That advice applies beyond geriatrics. Adults in their 30s and 40s taking first-generation antihistamines, muscle relaxants, or overactive-bladder drugs can experience the same anticholinergic fog.

A practical first step: calculate the patient's cumulative Anticholinergic Cognitive Burden (ACB) score. Each drug receives a score of 1 to 3. A total ACB score of 3 or higher is associated with a 1.5-fold increase in the odds of cognitive impairment over six years, per a longitudinal study in JAMA Internal Medicine (N=3,434) (3).

Drugs That Commonly Impair Concentration

The list is longer than most patients expect. Medications from at least seven therapeutic categories carry concentration-related warnings in their FDA-approved labeling, and the real-world frequency is higher than trial-reported rates because clinical studies often exclude cognitively impaired subjects (4).

Benzodiazepines and Z-drugs. Diazepam, alprazolam, lorazepam, and zolpidem all reduce working memory and psychomotor speed. A meta-analysis of 13 controlled studies found that long-term benzodiazepine users scored 0.74 standard deviations below matched controls on sustained-attention tasks (5). Deficits persisted for months after discontinuation in some participants.

Anticholinergics. Diphenhydramine (Benadryl), oxybutynin (Ditropan), tricyclic antidepressants like amitriptyline. These block muscarinic acetylcholine receptors in the cortex and hippocampus. The cognitive cost is dose-dependent and cumulative. A 2015 prospective cohort study (N=3,434) published in JAMA Internal Medicine showed a 54% increased dementia risk with high cumulative anticholinergic exposure over 10 years (6).

Opioids. Chronic opioid therapy impairs attention, processing speed, and executive function. A systematic review in Neuropsychology Review found consistent deficits across 13 of 15 included studies, independent of pain severity (7).

Lipophilic beta-blockers. Propranolol and metoprolol cross the blood-brain barrier more readily than atenolol or bisoprolol. CNS-penetrant beta-blockers have been linked to fatigue, mental slowing, and difficulty sustaining attention in a Cochrane review of hypertension trials (8).

Gabapentinoids. Gabapentin and pregabalin cause dose-related cognitive slowing. The prescribing information for pregabalin reports "difficulty with concentration/attention" in 1-6% of trial subjects, though real-world rates appear higher (9).

Topiramate. Nicknamed "Dopamax" by patients for a reason. Cognitive dysfunction (word-finding difficulty, slowed processing) occurs in up to 25% of users at doses above 200 mg/day (10).

How SSRIs and Other Antidepressants Affect Focus

The relationship between antidepressants and concentration is not straightforward. Depression itself impairs working memory, processing speed, and executive function. A well-chosen antidepressant can restore concentration by treating the underlying disease. The challenge is the interim period.

SSRIs (sertraline, fluoxetine, escitalopram) may cause "cognitive blunting" in the first 2-6 weeks, with some patients reporting emotional flattening that they describe as poor focus (11). A cross-sectional survey by Price et al. in Journal of Affective Disorders (N=854) found that 71% of SSRI-treated patients endorsed at least one cognitive-blunting symptom, though the authors could not fully separate drug effects from residual depression symptoms (11).

Bupropion (Wellbutrin) stands apart. Because it acts on dopamine and norepinephrine reuptake, it tends to preserve or improve concentration. A randomized trial comparing bupropion XL to escitalopram in major depressive disorder found superior performance on measures of psychomotor speed and executive function in the bupropion group at 8 weeks (12).

Dr. Andrew Cutler, Chief Medical Officer at Neuroscience Education Institute, has noted: "If a patient's chief cognitive complaint worsens on an SSRI, switching to bupropion or adding it as augmentation is a reasonable next move before layering on a stimulant."

Tricyclics (amitriptyline, nortriptyline) carry dual risk: anticholinergic burden plus sedation. In patients where concentration is a priority, nortriptyline is preferred over amitriptyline because its anticholinergic load is roughly one-third lower.

Stimulant Medications: The Primary Pharmacotherapy for Concentration

Methylphenidate (Ritalin, Concerta) and mixed amphetamine salts (Adderall, Vyvanse) remain the most effective pharmacological tools for restoring sustained attention. Their efficacy is best established in ADHD but extends to concentration deficits in other contexts.

In a landmark meta-analysis by Faraone and Glatt published in Neuropsychopharmacology, stimulants produced an effect size of 0.58 (95% CI 0.49-0.67) on inattention measures in adults with ADHD, a clinically meaningful and reproducible benefit (13). Response rates range from 70% to 80% when both stimulant classes are trialed.

Lisdexamfetamine (Vyvanse) has a smoother pharmacokinetic curve than immediate-release amphetamine because it requires enzymatic cleavage in the bloodstream. This translates to fewer end-of-dose concentration dips. The key trial (N=420) showed a 17.4-point improvement on the ADHD Rating Scale-IV vs. 6.3 points for placebo (14).

Methylphenidate extended-release (Concerta) uses an osmotic-release mechanism that delivers drug over 10-12 hours. It is often first-line in adults with cardiovascular risk factors because methylphenidate produces slightly smaller blood-pressure elevations than amphetamine at equipotent doses.

Stimulants are not appropriate for every concentration complaint. Prescribing requires a confirmed diagnosis (typically ADHD or narcolepsy), baseline cardiovascular screening, and ongoing monitoring. The American Academy of Pediatrics and the American Professional Society of ADHD and Related Disorders both recommend a thorough diagnostic evaluation before initiating stimulant therapy (15).

Non-Stimulant Options for Improving Concentration

Not every patient tolerates or wants stimulant medication. Several alternatives have randomized-controlled-trial support for attention improvement.

Atomoxetine (Strattera) is a selective norepinephrine reuptake inhibitor FDA-approved for ADHD. A pooled analysis of six adult ADHD trials (N=1,105) showed a mean effect size of 0.40 on inattention, smaller than stimulants but clinically significant (16). It takes 4-6 weeks to reach full effect. Side effects include nausea, dry mouth, and, in some patients, increased blood pressure.

Viloxazine ER (Qelbree) gained FDA approval for adult ADHD in 2023. In a phase-3 trial (N=373), viloxazine 400 mg/day reduced ADHD-RS-5 total scores by 7.9 points more than placebo (P<0.001) (17). It acts on both norepinephrine and serotonin, which may benefit patients with comorbid anxiety.

Guanfacine ER (Intuniv) is an alpha-2A agonist that strengthens prefrontal cortical function. While FDA-approved only in children, off-label use in adults is supported by a small controlled trial showing improved response inhibition and working memory at 1-4 mg/day (18).

Modafinil and armodafinil promote wakefulness and have some evidence for improving sustained attention in shift-work disorder and residual fatigue in depression, though they are not FDA-approved for ADHD. A double-blind crossover trial (N=32) found modafinil 200 mg improved digit-span accuracy and reaction time in healthy adults with sleep restriction (19).

Donepezil (Aricept) and other cholinesterase inhibitors are reserved for concentration deficits associated with mild cognitive impairment or Alzheimer's disease. Donepezil 10 mg/day produced a 2.8-point improvement on the ADAS-cog at 24 weeks in the key trial (N=473) (20).

How to Audit Your Medication List for Concentration Side Effects

A systematic medication review is more productive than guessing which drug is the culprit. The 2023 Beers Criteria and the STOPP/START tool provide evidence-based checklists for identifying cognitively harmful prescriptions (2).

Step 1: List every medication, including OTC drugs and supplements. Diphenhydramine-containing sleep aids (Tylenol PM, ZzzQuil) are among the most common hidden anticholinergic offenders.

Step 2: Score the anticholinergic burden. Free online calculators (search "ACB calculator") assign each drug a 1-3 score. Any cumulative score of 3 or higher warrants discussion.

Step 3: Identify temporal correlation. Did the concentration problem begin within weeks of starting or dose-increasing a specific drug? Drug-induced cognitive impairment usually appears within 1-4 weeks of initiation.

Step 4: Discuss deprescribing or substitution with the prescriber. Many offending medications have alternatives with lower cognitive cost. Cetirizine or loratadine can replace diphenhydramine. Mirabegron can replace oxybutynin. Atenolol can replace propranolol if a beta-blocker is still needed.

The Endocrine Society's 2019 Clinical Practice Guideline on testosterone therapy notes that "clinicians should consider medication-related cognitive effects as a differential diagnosis before attributing concentration complaints to hypogonadism" (21). That principle extends to any hormonal evaluation. Address the pharmacological cause first.

When Poor Concentration Requires a Specialist Evaluation

Medication audit alone is not always sufficient. If concentration does not improve after removing or substituting suspect drugs, or if the deficit was present before any medication use, further workup is appropriate.

Red flags that signal the need for neuropsychological or psychiatric evaluation include: progressive worsening over months, concentration loss accompanied by personality change or language errors, onset after head injury, and a family history of early-onset dementia. The American Academy of Neurology recommends formal neuropsychological testing for any cognitive complaint that persists beyond expected medication effects and is corroborated by an informant (22).

Thyroid dysfunction, B12 deficiency, sleep apnea, and untreated depression are medical causes that mimic or compound drug-induced cognitive impairment. A basic workup should include TSH, free T4, vitamin B12, CBC, CMP, and a validated sleep questionnaire.

Dr. Gayatri Devi, clinical professor of neurology at Zucker School of Medicine at Hofstra/Northwell, has stated: "The most common cause of treatable concentration problems in my practice is a combination of sleep deprivation and anticholinergic medication. Fix those two things, and many patients never need a stimulant."

Patients with ADHD confirmed by structured clinical interview (DIVA-5 or CAADID) and concentration impairment documented on neuropsychological testing are candidates for stimulant therapy. Those with mild cognitive impairment meeting NIA-AA criteria may benefit from cholinesterase inhibitors. The correct drug depends entirely on the correct diagnosis.